Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Deals
Biotech
Fosun pays $60M for option on AriBio’s phase 3 Alzheimer’s asset
Fosun Pharma secured the chance to expand its rights to the asset in exchange for a further $80 million.
Nick Paul Taylor
May 13, 2026 9:15am
Boehringer makes €407M bet on Immunitas’ inflammatory asset
May 12, 2026 9:57am
BMS inks $15B deal to bag Hengrui assets, tap China’s R&D speed
May 12, 2026 1:56am
Novo salvages happy ending for scrapped Parkinson’s therapy
May 11, 2026 8:30am
Banyan BioInnovations launches with $100M, Icon collab
May 7, 2026 2:13pm
Blackstone Invests $250M in Anagram to reduce CF pill burden
May 7, 2026 10:36am
